Literature DB >> 9712472

Nonlinear pharmacokinetics of fluvoxamine and gender differences.

S Härtter1, H Wetzel, E Hammes, M Torkzadeh, C Hiemke.   

Abstract

This prospective study assessed fluvoxamine serum concentrations under two different fixed doses. The study included 15 male and female patients who met the DSM-III-R criteria for major depression. They were prescribed 50 mg fluvoxamine twice a day for 2 weeks and 100 mg twice a day thereafter. Drug monitoring was carried out on days 14 and 28. Fluvoxamine serum concentrations were highly variable between patients. After the dose was doubled, the serum concentrations of fluvoxamine increased disproportionately (mean, 3.4-fold), and there was a significantly (p < 0.05) more pronounced increase in men (4.6-fold) than in women (2.4-fold). These results provide evidence of nonlinear, sex-dependent pharmacokinetics of fluvoxamine.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9712472     DOI: 10.1097/00007691-199808000-00016

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  7 in total

1.  A double-blind randomized study comparing imipramine with fluvoxamine in depressed inpatients.

Authors:  Walter W van den Broek; Tom K Birkenhäger; Paul G H Mulder; Jan A Bruijn; Peter Moleman
Journal:  Psychopharmacology (Berl)       Date:  2004-10       Impact factor: 4.530

Review 2.  Spotlight on fluvoxamine in anxiety disorders in children and adolescents.

Authors:  Susan M Cheer; David P Figgitt
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

Review 3.  How important are gender differences in pharmacokinetics?

Authors:  Bernd Meibohm; Ingrid Beierle; Hartmut Derendorf
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 4.  Fluvoxamine. An updated review of its use in the management of adults with anxiety disorders.

Authors:  D P Figgitt; K J McClellan
Journal:  Drugs       Date:  2000-10       Impact factor: 9.546

Review 5.  Fluvoxamine: a review of its therapeutic potential in the management of anxiety disorders in children and adolescents.

Authors:  S M Cheer; D P Figgitt
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

Review 6.  The role of sex, age and genetic polymorphisms of CYP enzymes on the pharmacokinetics of anticholinergic drugs.

Authors:  Shanna C Trenaman; Susan K Bowles; Melissa K Andrew; Kerry Goralski
Journal:  Pharmacol Res Perspect       Date:  2021-05

7.  The AGNP-TDM Expert Group Consensus Guidelines: focus on therapeutic monitoring of antidepressants.

Authors:  Pierre Baumann; Sven Ulrich; Gabriel Eckermann; Manfred Gerlach; Hans-Joachim Kuss; Gerd Laux; Bruno Müller-Oerlinghausen; Marie Luise Rao; Peter Riederer; Gerald Zernig; Christoph Hiemke
Journal:  Dialogues Clin Neurosci       Date:  2005       Impact factor: 5.986

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.